Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Study of REGN7257 in Severe Aplastic Anemia Refractory or Relapsed After Immunosuppressive Therapy
2023-508601-24-00Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 2 trial of REGN7257 in severe aplastic anemia (SAA) (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Safety and tolerability (Part A), Safety and tolerability (Part B) and 1 more. Started Jun 2024; status: completed.
02
Drugs
REGN7257
03
Conditions
severe aplastic anemia (SAA)
Beyond the preview
Go deeper on 2023-508601-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508601-24-00.